Fox Chase Cancer Center

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Fox Chase Cancer Center

Thoracic Malignancies: A Review of the Latest Evidence
2022 Management of Early Stage Non-Small Cell Lung Cancer
2022 Optimizing Treatment Strategies for Localized and Advanced Prostate Cancer
19th Annual Highlights of the 2020 San Antonio Breast Cancer Symposium
Genitourinary Malignancies in the Time of COVID-19
Videos
2019 Updates in Bladder and Kidney Cancer
Bladder Kidney
Events

Playback speed

10 seconds

2019 Update on Advanced RCC: Who Needs Treatment, Which 1st Line Drug (Ipi/Nivo, TKI/IO, or TKI Alone), and How to Sequence After 1st Line?

By Fox Chase Updates in Bladder and Kidney Cancer 2019 FEATURING Daniel Geynisman

1,548 views

December 16, 2019

Daniel M. Geynisman, MD, Fox Chase Cancer Center, Philadelphia, PA

Dr. Geynisman is an Assistant ...
read more ↘ Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center. He specializes in treating patients with genitourinary malignancies, including prostate, bladder, kidney, testicular, penile and adrenal cancers. Dr. Geynisman has co-authored more than 75 manuscripts in peer-reviewed journals. His research focuses on health outcomes and clinical trials development for genitourinary cancers. He serves on the NCCN guideline panel for testicular cancers and is an assistant editor for Urologic Oncology.

Dr. Geynisman earned his medical degree from the University of Pittsburgh School of Medicine and completed a residency in internal medicine at the University of Pittsburgh Medical Center, serving an additional year as chief resident. He went on to complete a fellowship in hematology/oncology at the University of Chicago, serving as a chief fellow in his final year of training.
↖ read less

Comments 1